Mantle Cell Lymphoma
From the Journals
Rituximab maintenance halves MCL death risk after ASCT
The rate of 4-year event-free survival was 79% for patients maintained on rituximab vs. 61% for those on observation alone.
From the Journals
Plerixafor doesn’t overcome HPC failure in R-hyperCVAD for mantle cell lymphoma
Even with plerixafor, HPC failure was more common when mantle cell lymphoma patients received R-hyperCVAD.
News
FDA grants priority review of acalabrutinib for second-line treatment of MCL
Acalabrutinib for treatment of patients with mantle cell lymphoma has been granted priority review by the FDA.
Latest News
IMiD/Anti-CD20 combo induces complete responses in r/r NHL
Lugano, Switzerland – A combination of obinutuzumab (Gazyva) and the experimental immunomodulatory agent CC-122 showed “clinically meaningful”...
Conference Coverage
Chemo-free induction in MCL keeps getting better
Lugano, Switzerland –
Conference Coverage
Bendamustine plus rituximab may have edge for treating indolent NHL, MCL
CHICAGO – Bendamustine plus rituximab may have some advantages for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle cell...
Conference Coverage
Hitting BTK, PI3K pays off in B-cell malignancies
Umbralisib, a second-generation PI3K inhibitor, appears to have a better safety profile than the first-in-class agent idelalisib.
From the Journals
Liposomes boost bortezomib efficacy
Liposomes might be able to boost efficacy and reduce side effects of bortezomib.
Conference Coverage
Early allo SCT advised for high-risk mantle cell lymphoma
High-risk patients with mantle cell lymphoma who have a matched related donor have a better chance for survival if they do not delay allogeneic...
Conference Coverage
ALC/AMC prognostic in mantle cell lymphoma
The peripheral blood absolute lymphocyte-to-monocyte ratio (ALC/AMC) was prognostic for overall survival in mantle cell lymphoma patients who have...
Physician Resources
CAR T-cell data expected soon in mantle cell lymphoma
How might a new trial, ZUMA-2, affect mantle cell lymphoma treatment once completed?